COVID Vaccination as a Strategy for Cardiovascular Disease Prevention

Curr Cardiol Rep. 2023 Oct;25(10):1327-1335. doi: 10.1007/s11886-023-01950-2. Epub 2023 Sep 9.

Abstract

Purpose of review: Cardiovascular (CV) disease is a known complication of SARS-CoV-2 infection. A clear benefit of COVID-19 vaccination is a reduction mortality; however, COVID-19 vaccination may also prevent cardiovascular disease (CVD). We aim to describe CV pathology associated with SARS-CoV-2 infection and describe how COVID-19 vaccination is a strategy for CVD prevention.

Recent findings: The risks and benefits of COVID-19 vaccination have been widely studied. Analysis of individuals with and without pre-existing CVD has shown that COVID-19 vaccination can prevent morbidity associated with SARS-CoV-2 infection and reduce mortality. COVID-19 vaccination is effective in preventing myocardial infarction, cerebrovascular events, myopericarditis, and long COVID, all associated with CVD risk factors. Vaccination reduces mortality in patients with pre-existing CVD. Further study investigating ideal vaccination schedules for individuals with CVD should be undertaken to protect this vulnerable group and address new risks from variants of concern.

Keywords: COVID; Cardiovascular disease; Vaccination.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Cardiovascular Diseases* / prevention & control
  • Humans
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines